all report title image
  • Published On : Sep 2022
  • Code : CMI5252
  • Industry : Pharmaceutical
  • Pages : 175
  • Formats :

Hypoglycemia is a condition when blood sugar levels drop below 70 mg/dL. Low blood sugar is especially common in people with type 1 diabetes. Hypoglycemic drugs are anti-diabetic drugs designed to help people with type 1 diabetes manage their condition. The major oral hypoglycemics drug types are:

  • Biguanides,
  • Alpha-glucosidase inhibitors,
  • Sulphonylureas,
  • Thiazolidinediones (Glitazones)
  • Dipeptidyl peptidase-4 (DPP-4) inhibitors
  • Glucagon

Global hypoglycemic drugs market is estimated to be valued at US$ 660 Mn in 2022 and is expected to exhibit a CAGR of 9.2% during the forecast period (2022-2030).

Figure 1. Global Hypoglycemic Drugs Market, in Terms of Value (US$ Million), By Region, 2022

Hypoglycemic Drugs  | Coherent Market Insights

Increasing prevalence of diabetes is expected to drive the global hypoglycemic drugs market growth during the forecast period.

Increasing prevalence of diabetes is expected to drive the global hypoglycemic drugs market growth over the forecast period. For instance, according to a report published by International Diabetes Federation 2021, it is estimated that 1 in 11 adults have diabetes – (61 million), 1 in 3 (36%) people living with diabetes are undiagnosed in Europe, 1 in 7 live births are affected by hyperglycaemia in pregnancy. The Europe Region has the highest number of children and adolescents with type 1 diabetes – 295,000.

CMI table icon

Hypoglycemic Drugs Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 660 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 9.2% 2030 Value Projection: US$ 1,420 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Sulphonylureas, Biguanides, Alpha-glucosidase inhibitors, Thiazolidinediones, Dipeptidylpeptidase-4 (DPP-4) inhibitors, Glucagon
  • By Route of Administration: Oral, Injectable, Nasal
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceutica NV,  Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc.,  Novartis AG., Novo Nordisk A/S, Teva Pharmaceuticals Pvt Ltd., and  Sun Pharmaceutical Industries Ltd

Growth Drivers:
  • Increasing prevalence of diabetes
  • Increasing number of drug approvals from regulatory bodies
Restraints & Challenges:
  • Drug recalls

Figure 2. Global Hypoglycemic Drugs Market Share (%), By Drug Class, 2022

Hypoglycemic Drugs  | Coherent Market Insights

Increasing product approvals from regulatory bodies is expected to drive the global hypoglycemic drugs market growth over the forecast period.

Market players are focused on gaining approvals from regulatory bodies, which is expected to boost growth of the global hypoglycemic drugs market. For instance, in July 2019, Eli Lilly and Company, a pharmaceutical company, announced that it had received approval from the U.S. Food and Drug Administration, for Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an injection.

Global Hypoglycemic Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

COVID-19 has resulted in several challenges in healthcare sector. Due to lockdown it created disruptions for the patients to visit Diabetic centers. According to an article published by Diabetes Canada, University Avenue, Canada in 2021, a study was conducted by researchers of University Avenue for the situation of diabetic patients during COVID-19. It was concluded that the rates of hypoglycemia appeared to be mixed, depending on type of diabetes. Data from Spain and Italy, examining glycemic management during the early days of lockdown, showed either no change in the frequency incidence of hypoglycemia in adults with type 1 diabetes or a decrease in the hypoglycemic events. In an Italian study of children with type 1 diabetes, there was a slight decrease in the number of cases of severe hypoglycemia reported in 2020 versus the same time period in 2019. Moreover, another Spanish study also reported no significant increase in hypoglycemiacfor people with type 1 diabetes.

Global Hypoglycemic Drugs Market: Restraints

Drug recalls from market players are expected to hinder growth of the global hypoglycemic drugs market. For instance, in June 2021, US FDA had alerted patients and health care professionals about Nostrum Laboratories’ voluntary recall of one additional lot of extended release (ER) metformin. The company had recalled the lot because the metformin may have contained N-nitrosodimethylamine (NDMA) above the acceptable intake limit.

Similarly, in May 2020, Marksans Pharma and Sun Pharmaceutical Industries Limited., announced voluntary recall of extended release (ER) metformin. The companies had recalled metformin because it may have contained N-nitrosodimethylamine (NDMA) above the acceptable intake limit.

Key Players                   

Major players operating in the global hypoglycemic drugs market include Eli Lilly & Company,  Boehringer Ingelheim GmbH,  Vistin Pharma AS,  Janssen Pharmaceutica NV,  Sanofi,  Astellas Pharma Inc.,  AstraZeneca plc.,  Merck & Co., Inc.,  Novartis AG.,  Novo Nordisk A/S,  Teva Pharmaceuticals Pvt Ltd., and  Sun Pharmaceutical Industries Ltd.

Hypoglycemia is a condition in which blood sugar (glucose) level is lower than the standard range. Glucose is the main energy soiurce for the body. Hypoglycemia is often related to diabetes treatment. Hypoglycemia occurs when the level of glucose present in the blood falls below a set point, i.e., below 4 mmol/L (72mg/dL). The symptoms associated with Hypogyclemia are, sweating, fatigue, feeling dizzy, feeling weak, blurred vision, and others. Hypoglycemia is detected by measuring blood sugar levels with a glucose meter. Any blood glucose level below 4.0 mmol/L indicates that the individual has hypoglycemia.

Market Dynamics

Increasing prevalence of diabetes is expected to drive growth of the global hypoglycemic drugs market. For instance, according to an article published by American Diabetes Association on 28 July 2022, in 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. Nearly 1.9 million Americans had type 1 diabetes, including about 244,000 children and adolescents. 1.4 million Americans are diagnosed with diabetes every year.according to same soruce, In 2014–2015, the annual incidence of diagnosed diabetes in youth was estimated at 18,200 with type 1 diabetes and 5,800 with type 2 diabetes.

Increasing number of drug approvals from regulatory bodies is expected to drive growth of the global hypoglycemic drugs market. For instance, in December 2020, Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid.

Key features of the study:

  • This report provides an in-depth analysis of the global hypoglycemic drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global hypoglycemic drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
  • Key companies covered as a part of this study include Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceuticals NV, Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Teva Pharmaceuticals Pvt Ltd., and Sun Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global hypoglycemic drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global hypoglycemic drugs market

Detailed Segmentation:

  • Global Hypoglycemic Drugs Market, By Drug Class:
    • Sulphonylureas
    • Biguanides
    • Alpha-glucosidase inhibitors
    • Thiazolidinediones (Glitazones)
    • Dipeptidyl peptidase-4 (DPP-4) inhibitors
    • Glucagon
  • Global Hypoglycemic Drugs Market, By Route of Administration:
    • Oral
    • Injectable
    • Nasal
  • Global Hypoglycemic Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hypoglycemic Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Eli Lilly & Company*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Boehringer Ingelheim GmbH
    • Vistin Pharma AS
    • Janssen Pharmaceuticals NV
    • Sanofi
    • Astellas Pharma Inc.
    • AstraZeneca plc.
    • Merck & Co., Inc.
    • Novartis AG
    • Novo Nordisk A/S
    • Teva Pharmaceuticals Pvt Ltd.
    • Sun Pharmaceutical Industries Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global hypoglycemic drugs market is estimated to be valued at US$ 660 million in 2022 and is expected to exhibit a CAGR of 9.2% between 2022 and 2030.
Increasing prevalence of diabetes and increasing product approvals from regulatory bodies are expected to drive the market growth over the forecast period.
Biguanides segment is holding a major market share in the market.
Drug recall is expected to hamper growth of the market.
Major players operating in the market include Eli Lilly & Company,  Boehringer Ingelheim GmbH,  Vistin Pharma AS,  Janssen Pharmaceutica NV,  Sanofi,  Astellas Pharma Inc.,  AstraZeneca plc.,  Merck & Co., Inc.,  Novartis AG.,  Novo Nordisk A/S,  Teva Pharmaceuticals Pvt Ltd., and  Sun Pharmaceutical Industries Ltd.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo